Multicenter Randomized Active-controlled Study to Investigate Efficacy & Safety of IV FCM in Pediatric Patients With IDA

Phase 3

Completed

• Conditions: Iron Deficiency Anemia
• Interventions: Drug: Ferrous Sulfate; Drug: Ferric carboxymaltose

• Registration Number: NCT03523117
• Lead Sponsor: American Regent, Inc.

Brief Summary

The primary objective of this study is to demonstrate the efficacy and safety of intravenous ferric carboxymaltose (FCM), compared to oral iron, in pediatric participants who have iron deficiency anemia.

Detailed Description

This is a Phase III, multicenter, randomized, active-controlled study that compares the efficacy and safety of FCM to oral iron in pediatric participants with IDA and a documented history of an inadequate response to oral iron therapy at least 8 weeks (56 days) prior to randomization.

Participants who satisfy the inclusion requirements and no exclusion criteria will be eligible to participate in this study and enter into a screening phase to confirm eligibility. Randomization will occur via the Interactive Response Technology (IRT) system in a 1:1 ratio to either Group A, participants receiving FCM, or Group B, participants receiving oral iron (oral solution drops, elixir or oral tablets). Randomization will be stratified by baseline Hgb (\<10, ≥10 g/dL) and age (1 to \<12 years and ≥12 to 17 years).

The oral ferrous sulfate formulation received will be based on the participant's age, such that infants and children (1 to \<4 years of age) will receive ferrous sulfate drops, children (≥4 to \<12 years of age) will receive ferrous sulfate elixir, and adolescents (≥12 to 17 years of age) will receive ferrous sulfate tablets. Participants who experience adverse clinical symptoms due to the oral iron during the treatment phase may have a weight-based dose of ferrous sulfate reduced from 6 mg/kg to 3 mg/kg. If the participant is receiving tablets, the dose will be reduced from one tablet taken twice daily to one tablet per day.

Once randomized, all participants will return for efficacy and safety evaluations, including adverse events and laboratory assessments, on Days 7, 14, 28, and 35. Additional pharmacokinetic sampling and analyses will be performed for participants receiving FCM on Days 0 and 7.

Study Timeline

• Study First Submitted: 2018-04-17
• Study First Submitted QC: 2018-05-01
• Study First Posted: 2018-05-14
• Study Start: 2019-01-31
• Primary Completion: 2020-12-22
• Study Completion: 2021-01-29
• Results First Submitted: 2021-10-27
• Status Verified: 2022-05
• Results First Submitted QC: 2022-05-26
• Last Update Submitted: 2022-05-26
• Results First Posted: 2022-06-22
• Last Update Posted: 2022-06-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 79

Inclusion Criteria

1. Male or female participants 1 to 17 years of age with assent to participation and his/her parent or guardian is willing and able to sign the informed consent approved by the Independent Review Board / Ethics Committee.
2. Screening Hgb <11 g/dL.
3. Screening ferritin ≤300 ng/mL and transferrin saturation (TSAT) <30%.
4. Participants must have a documented history of an inadequate response to any oral iron therapy for at least 8 weeks (56 days) prior to randomization.
5. For participants who are receiving an erythropoietin stimulating agent (ESA): stable ESA therapy (+/- 20% of current dose) for at least 8 weeks prior to the qualifying screening visit and no ESA dosing or product changes anticipated for the length of the trial.
6. Participants undergoing treatment for inflammatory bowel disease (IBD) must be on stable therapy for at least 8 weeks prior to consent.

Exclusion Criteria

1. Known history of hypersensitivity reaction to any component of FCM.
2. Previous randomization and treatment in this study or any other clinical study of FCM or VIT-45.
3. History of acquired iron overload, hemochromatosis, or other iron accumulation disorders.
4. Chronic kidney disease participants on hemodialysis.
5. History of significant diseases of the liver, hematopoietic system, cardiovascular system, psychiatric disorder, or other conditions which, on the opinion of the investigator, may place a subject at added risk for participation in the study.
6. Any existing non-viral infection.
7. Known history of positive hepatitis B antigen (HBsAg) or hepatitis C viral antibody (HCV) with evidence of active hepatitis.
8. Known history of positive HIV-1/HIV-2 antibodies (anti-HIV).
9. Anemia due to reasons other than iron deficiency (e.g., hemoglobinopathy and vitamin B12 or folic acid deficiency) that has not been corrected.
10. Intravenous iron and /or blood transfusion in the 4 weeks prior to consent.
11. Administration and / or use of an investigational product (drug or device) within 30 days of screening.
12. Alcohol or drug abuse within the past six months.
13. Female participant who is pregnant or lactating, or sexually active female who are of childbearing potential not willing to use an acceptable form of contraceptive precautions during the study.
14. Unable to comply with study procedures and assessments

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Oral Ferrous Sulfate	Ferrous Sulfate	Oral Ferrous Sulfate - will receive an age-dependent formulation of oral ferrous sulfate daily for 28 days as follows: participants \<12 years of age will receive 6 mg (elemental iron)/kg/day divided into 2 daily doses of an oral liquid formulation, either drops or elixir, and participants ≥12 will receive 2 daily doses of oral tablets. Infants and children (ages 1 to \<4 years) will receive oral ferrous sulfate drops, while children (ages ≥4 to \<12 years) will receive oral ferrous sulfate elixir. Adolescents (ages ≥12 to 17 years) will receive an oral ferrous sulfate tablet (65 mg of elemental iron/tablet/dose) twice a day (BID). The maximum daily dose for all participants is 130 mg of elemental iron.
Ferric Caroboxymaltose	Ferric carboxymaltose	Ferric Carboxymaltose - 2 doses (day 0 and day 7) at 15 mg/kg to a maximum single dose of 750 mg (whichever is smaller) up to a maximum of total dose of 1500 mg administered as either an undiluted IV push at a rate of 100 mg (2mL)/minute OR in no more than 250 mL of normal saline and infused over 15 minutes.

Primary Outcome Measures

Name	Time	Method
Change in Hemoglobin g/dL	Baseline to day 35	Change in hemoglobin g/dL from baseline to day 35 will be analyzed using parametric analysis of covariance (ANCOVA). The model will include terms for the randomization strata (hemoglobin and age categories), baseline hemoglobin, as well as treatment group. Baseline hemoglobin will be defined as the last hemoglobin obtained before randomization.

Secondary Outcome Measures

Name	Time	Method
Change in TSAT (%) From Baseline to Day 35	Baseline to day 35	Change in TSAT (%) from baseline to day 35 was analyzed using parametric analysis of covariance (ANCOVA). The model included terms for the randomization strata (hemoglobin and age categories), baseline ferritin as a covariate
Change in Ferritin µg/L From Baseline to Day 35	Baseline to day 35	Change in ferritin µg/L from baseline to day 35 was analyzed using parametric analysis of covariance (ANCOVA). The model included terms for the randomization strata (hemoglobin and age categories), baseline ferritin as a covariate.
Change in Reticulocyte Hemoglobin (Picograms) Content From Baseline to Day 35	Baseline to day 35	Change in reticulocyte hemoglobin (picograms) content from baseline to day 35 was analyzed using a mixed model repeated. The model included terms for the randomization strata (hemoglobin and age categories), baseline ferritin as a reticulocyte hemoglobin content.

Trial Locations

Locations (16)

ProHealth Research Center; 🇺🇸 Doral, Florida, United States

Garden Medical Research, Inc.; 🇺🇸 Miami, Florida, United States

Miami Clinical Research; 🇺🇸 Miami, Florida, United States

Riley Hospital for Children,Room 4340; 🇺🇸 Indianapolis, Indiana, United States

Caro Health Plaza; 🇺🇸 Caro, Michigan, United States

South Florida Research Phase I-IV; 🇺🇸 Miami Springs, Florida, United States

Arkansas Children's Hospital; 🇺🇸 Little Rock, Arkansas, United States

International Research Partners, Inc.; 🇺🇸 Doral, Florida, United States

Galen Research; 🇺🇸 Chesterfield, Missouri, United States

Tiga Pediatrics, PC; 🇺🇸 Bronx, New York, United States

Cincinnati Children's Hospital and Medical Center; 🇺🇸 Cincinnati, Ohio, United States

Cincinnati Children's Hospital Medical Center; 🇺🇸 Cincinnati, Ohio, United States

Baylor College of Medicine/Texas Children Hospital; 🇺🇸 Houston, Texas, United States

Cook Children's Medical Center; 🇺🇸 Fort Worth, Texas, United States

Tekton Research; 🇺🇸 San Antonio, Texas, United States

Aspen Clinical Research; 🇺🇸 Orem, Utah, United States